Kamada Ltd. KMDA
Biotechnology: Pharmaceutical Preparations · IPO 2013 · data as of November 13, 2026
Kamada Ltd. (KMDA) is a healthcare company listed in the US with a market value of about $467M. In the twelve months to September 30, 2026 it had revenue of $197M and net income of $25M, a net margin of 12.7%.
Its overall Stock Analiz score is 2.8 out of 5 (average). The strongest part is financial health (5/5); the weakest is track record (0/5).
Key numbers: a P/E of 21.3, a price to free cash flow of 13.0, 5-year revenue growth of 6% a year, a 5-year average ROIC of 4%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 25% below the current price.
About Kamada
Kamada is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2013. Revenue went from $70M in 2015 to $180M in 2025, growth of about 9.9% a year. It was profitable in 7 of the last 10 years in our data.
Score: 2.8 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- More cash than debt, or low debt to equity
- Positive free cash flow
Checks not passed
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $197M | $180M | $161M | $143M | $129M | $104M | $133M | $127M | $114M | $103M | $77M |
| Net income | $25M | $20M | $14M | $8M | -$2M | -$2M | $17M | $22M | $22M | $7M | -$7M |
| Free cash flow | $36M | $16M | $37M | -$2M | $25M | -$13M | $14M | $25M | $8M | -$559000 | -$744000 |
| EPS (diluted) | $0.43 | $0.35 | $0.25 | $0.14 | $-0.04 | $-0.04 | $0.30 | $0.39 | $0.39 | $0.12 | $-0.12 |
| Net margin | 12.7% | 11.2% | 9.0% | 5.8% | -1.8% | -2.1% | 12.9% | 17.5% | 19.5% | 6.7% | -8.7% |
| ROIC | — | 8.4% | 6.1% | 4.0% | 1.8% | -0.3% | 9.9% | 16.2% | 13.4% | 7.8% | -6.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 4 analysts is $13.75, 70% above the current price; targets range from $12.00 to $15.00; the consensus rating is “Strong buy”; expected EPS is $0.47 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Kamada’s P/E ratio?
About 21.3, based on the last twelve months of diluted earnings per share (forward P/E about 15.6).
Is Kamada stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 25% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Kamada pay a dividend?
Yes. The dividend yield is about 2.11%, and it has paid dividends for 1 years in our data.
Is Kamada a good stock to buy?
We do not give buy or sell advice. Kamada scores 2.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.